# OnCo record tegafur-gimeracil-oteracil (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/tegafur-gimeracil-oteracil/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "tegafur-gimeracil-oteracil" ;
  schema:name "Tegafur, gimeracil and oteracil (S-1)"@en ;
  schema:alternateName "S-1"@en, "TS-1"@en, "Teysuno" ;
  schema:description "Teysuno (S-1) is an oral chemotherapy combining a fluorouracil pro-drug with two protectors. It is a standard in Japan and approved in Europe for stomach cancer with cisplatin and for bowel cancer when other fluoropyrimidines cause hand-foot syndrome or heart problems."@en ;
  schema:url <https://onco.cc/drugs/tegafur-gimeracil-oteracil/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Tegafur/gimeracil/oteracil> ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno>, <https://doi.org/10.1016/S0140-6736(16)30583-9>, <https://doi.org/10.1200/JCO.2012.43.3680> ;
  onco:status "approved" ;
  onco:tag "ema-list" ;
  onco:modality "Oral fluoropyrimidine combination (antimetabolite)" ;
  onco:approval "JP 1999: Gastric cancer; later colorectal, head and neck, lung, pancreatic, biliary and breast cancer (TS-1)", "EU 2011: Advanced gastric cancer with cisplatin; metastatic colorectal cancer intolerant of other fluoropyrimidines added 2022 (Teysuno)" ;
  onco:related <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:companies <https://onco.cc/companies/taiho/> ;
  onco:terms <https://onco.cc/terms/prodrug/> ;
  onco:trials <https://onco.cc/trials/jaspac-01/>, <https://onco.cc/trials/nct07262567/>, <https://onco.cc/trials/nct00660894/>, <https://onco.cc/trials/nct03448549/> .